Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

National Pest Management Association Separates Pest Myths From Pest Facts
As summer pests are a natural part of the outdoors and typically viewed simply as a nuisance, many believe that they have a full understanding of the risks associated with such. Yet, the National Pest Management Association (NPMA) warns that there are a multitude of myths about summer insects that homeowners subscribe to - most of which wrongly minimize the threats of stinging insects, mosquitoes and ants.
generic viagra online
Obesity And Migraine Sufferers More Emotionally Traumatized Than Those With Life-Threatening Conditions
Need another reason to commit to a healthy diet and exercise? Think migraines are just headaches? Migraine and obesity sufferers feel more emotional pain than those dealing with life-threatening conditions like congestive heart failure, prostate cancer, osteoporosis and high blood pressure. In fact, they tend to feel more pessimistic than those diagnosed with depression.
News of the day
Australian Medical Students' Association: Medical Students Can't Learn Without Teachers
The Australian Medical Students" Association acknowledges the Australian Medical Association"s call for action concerning the difficulties that doctors face in maintaining involvement in teaching and research activities.
Medical Devices

2009/039 NICE Guidance Recommends Lenalidomide For Multiple Myeloma

The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of lenalidomide for multiple myeloma in people who have received at least one prior therapy. The new NICE guidance recommends lenalidomide in combination with dexamethasone as a treatment option for people with multiple myeloma who have received two or more prior therapies. The cost of the drug beyond 26 cycles (each of 28 days; normally a period of 2 years) will be met by the manufacturer, Celgene. For those patients who have not received two or more prior therapies, but are currently receiving lenalidomide, the independent Appraisal Committee has recommended they have the option to continue treatment until they and their clinician consider it appropriate to stop. Professor Peter Littlejohns, Clinical and Public Health Director at NICE said: "Multiple myeloma is a type of cancer that develops from cells in the bone marrow and there is currently no cure for the disease, only treatments to stop the progress of the condition and help relieve symptoms. It is an uncommon cancer, with less than 4000 new cases per year in the UK. "Following a proposal from the manufacturer of lenalidomide, where they bear the costs of the drug beyond 26 cycles (normally for a period of 2 years), the independent Appraisal Committee was able to recommend lenalidomide as treatment option for multiple myeloma in people who have received two or more prior therapies. The Committee also accepted that lenalidomide fitted NICE"s criteria for allowing its advisory bodies greater flexibility when making recommendations on the use of end of life treatments. "NICE already recommended bortezomib (Velcade) in October 2007 under a risk sharing scheme for patients who are experiencing their first relapse and publication of this new NICE guidance is good news for patients who have already tried other chemotherapy regimens." National Institute for Health and Clinical Excellence


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009